Delving into the Latest Updates on Trametes versicolor Extract with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Coriolus Versicolor Extract

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Unresectable Hepatocellular Carcinoma

Originator Organization

National University Hospital

Active Organization-

Inactive Organization

National University Hospital

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

Start Date25 Oct 2024

Sponsor / Collaborator

Mayo Clinic

NCT01097083 / TerminatedPhase 2IIT

A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy

The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months

Start Date01 Apr 2010

Sponsor / Collaborator

National University Hospital

NCT00680667 / CompletedPhase 1IIT

Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer

RATIONALE: Coriolus versicolor mushroom extract may slow the growth of cancer cells and may be an effective treatment for breast cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of coriolus versicolor extract in treating women with stage I, stage II, or stage III breast cancer who have finished radiation therapy.

Start Date01 Apr 2007

Sponsor / Collaborator

University of Minnesota Masonic Cancer Center

[+1]

100 Clinical Results associated with Trametes versicolor Extract

Login to view more data

100 Translational Medicine associated with Trametes versicolor Extract

Login to view more data

100 Patents (Medical) associated with Trametes versicolor Extract

Login to view more data

23

Literatures (Medical) associated with Trametes versicolor Extract

01 Feb 2024·Mycotoxin Research

Immobilization of recombinant Trametes versicolor aflatoxin B1-degrading enzyme (TV-AFB1D) with montmorillonite for absorption and in situ degradation of aflatoxin B1

Article

Author: Zheng, Zhi ; Lu, Shuhua ; Wu, Wenjing ; Jiang, Shaotong ; Jiang, Suwei ; Yang, Peizhou ; Chen, Jianchao

Aflatoxin B₁ is a highly carcinogenic and teratogenic substance mainly produced by toxin-producing strains such as Aspergillus flavus and Aspergillus parasitic. The efficient decomposition of aflatoxin is an important means to reduce its harm to humans and livestock. In this study, Trametes versicolor aflatoxin B₁-degrading enzyme (TV-AFB₁D) was recombinantly expressed in Bacillus subtilis (B. subtilis) 168. MMT-CTAB-AFB₁D complex was prepared by the immobilization of TV-AFB₁D and montmorillonite (MMT) by cross-linking glutaraldehyde. The results indicated that TV-AFB₁D could recombinantly express in engineered B. subtilis 168 with a size of approximately 77 kDa. The immobilization efficiency of MMT-CTAB-AFB₁D reached 98.63% when the concentration of glutaraldehyde was 5% (v/v). The relative activity of TV-AFB₁D decreased to 72.36% after reusing for 10 times. The content of AFB₁ in MMT-CTAB-AFB₁D-AFB₁ decreased to 1.1 µg/g from the initial 5.6 µg/g after incubation at 50 °C for 6 h. The amount of 80.4% AFB₁ in the MMT-CTAB-AFB₁D-AFB₁ complex was degraded by in situ catalytic degradation. Thus, the strategy of combining adsorption and in situ degradation could effectively reduce the content of AFB₁ residue in the MMT-CTAB-AFB₁D complex.

27 Jul 2023·Antioxidants (Basel, Switzerland)

Modulation of TLR4/NFκB Pathways in Autoimmune Myocarditis.

Article

Author: Genovese, Tiziana ; Cordaro, Marika ; D'Agostino, Melissa ; D'Amico, Ramona ; Crupi, Rosalia ; Gugliandolo, Enrico ; Interdonato, Livia ; Siracusa, Rosalba ; Fusco, Roberta ; Impellizzeri, Daniela ; Di Paola, Rosanna ; Cuzzocrea, Salvatore

Myocarditis is an inflammatory and oxidative disorder characterized by immune cell recruitment in the damaged tissue and organ dysfunction. In this paper, we evaluated the molecular pathways involved in myocarditis using a natural compound, Coriolus versicolor, in an experimental model of autoimmune myocarditis (EAM). Animals were immunized with an emulsion of pig cardiac myosin and complete Freund's adjuvant supplemented with mycobacterium tuberculosis; thereafter, Coriolus versicolor (200 mg/Kg) was orally administered for 21 days. At the end of the experiment, blood pressure and heart rate measurements were recorded and the body and heart weights as well. From the molecular point of view, the Coriolus versicolor administration reduced the activation of the TLR4/NF-κB pathway and the levels of pro-inflammatory cytokines (INF-γ, TNF-α, IL-6, IL-17, and IL-2) and restored the levels of anti-inflammatory cytokines (IL-10). These anti-inflammatory effects were accompanied with a reduced lipid peroxidation and nitrite levels and restored the antioxidant enzyme activities (SOD and CAT) and GSH levels. Additionally, it reduced the histological injury and the immune cell recruitment (CD4⁺ and CD68⁺ cells). Moreover, we observed an antiapoptotic activity in both intrinsic (Fas/FasL/caspase-3) and extrinsic (Bax/Bcl-2) pathways. Overall, our data showed that Coriolus versicolor administration modulates the TLR4/NF-κB signaling in EAM.

01 Apr 2021·Journal of Lower Genital Tract DiseaseQ4 · MEDICINE

Efficacy of a Coriolus versicolor–Based Vaginal Gel in Women With Human Papillomavirus–Dependent Cervical Lesions: The PALOMA Study

Q4 · MEDICINE

Article

Author: Palacios, Santiago ; Vanrell, Cristina ; López, José Antonio ; de la Fuente, Jesús ; Serrano, Luis ; Dexeus, Damián ; Centeno-Mediavilla, Cristina ; López, Andrés Carlos ; Coronado, Pluvio ; Cortés, Javier ; González, Silvia P.

ObjectiveThe aim of the study was to evaluate the efficacy of Papilocare, a Coriolus versicolor–based vaginal gel, in repairing human papillomavirus (HPV)-related low-grade cervical lesions.MethodsThe study is a multicenter, open-label, randomized, parallel-group, watchful waiting approach-controlled trial involving 91 HPV-positive women with low-grade Pap smear alterations and consistent colposcopy.ResultsThe percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity.ConclusionsTreatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for total and high-risk HPV patients in terms of its efficacy to treat HPV-related cervical lesions and to clear all HPV strains after a single 6-month period. It has demonstrated an adequate safety and tolerability and confers additional benefits such as higher re-epithelization, stress reduction, and high treatment adherence.

100 Deals associated with Trametes versicolor Extract

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Unresectable Hepatocellular Carcinoma	Phase 2	SG	National University Hospital	01 Apr 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Paloma Clinical Trial (ESGO2023)	Phase 3	Human Papillomavirus Infection \| Visible Lesion HR-HPV	20	Papilocare®	(yyylcvrvzj) = ijdgdpwcgm vsofpeqbit (odkqxezmmf )	Positive	27 Sep 2023
				coriolus versicolor	(yyylcvrvzj) = fpcbfjdpfq vsofpeqbit (odkqxezmmf )